Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L22 pseudogene 1 (RPL22P1) is a processed pseudogene derived from the functional RPL22 gene. Pseudogenes are DNA sequences similar to known genes but typically non-functional as proteins. RPL22P1 does not encode a functional ribosomal protein, but may be transcribed into RNA. Recent research shows some pseudogene RNAs, including lncRNAs, can be translated or serve as regulatory molecules, but the biological significance of RPL22P1 is unclear; its function, if any, is likely unrelated to classical protein or receptor roles[1][6]. RPL22P1 is not considered a therapeutic target, lacks known drug interactions, mechanism of action, or biomarker status. Its primary relevance is as a genomic element with sequence similarity to RPL22[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L22 pseudogene 1 (RPL22P1).